Asia Regulatory Strategy

CSOFT’s expert consultants provide our clients with insight into China’s pharmaceutical industry and help strategize regulatory and commercialization plans. We strive to ease complex issues our clients are facing such as obtaining the NMPA’s approval to register as well as to incorporate new medical products into China’s market.
Contact us now
Home 9 Asia Regulatory Services 9 Asia Regulatory Strategy

Before introducing new drugs into the Chinese market, companies must obtain approval from NMPA and create proper pricing and branding for the products. We will work directly with your team to perform a comprehensive analysis to evaluate business opportunities versus risk factors.

The consultant team will give our clients specific guidelines on how to register their medical products and obtain faster approval from the NMPA. Afterward, we will design a plan to launch the product into China’s market and assist its implementation. Our team is dedicated to minimizing our clients’ risk while maximizing their business value and profits.

Medical Product Registration

Methodology

Research

  • Data analytics & evaluation skills
  • Product gap analysis
  • Access to first-hand
    market data & intelligence
  • Access to first-hand
    market data & intelligence

Deliverables

  • Market research reports
  • Data summaries
  • Proposals
  • Comments & feedback

Consulting

  • Medical market
  • Healthcare system
  • Pharmaceutical regulations
  • Latest updates and revisions to regulations
  • Cultural and linguistic differences

Communications

  • RA executives
  • International marketing and sales team
  • Key opinion leaders (KOLs)
  • Local experts in NMPA regulations and clinical trials in China market